View Older Stories View More Recent Stories
-
Stocks expected to have increasing option volume: LLY NVO VKTX AXP OZK TFC SLB FITB HBAN ALLY CME RGTI QUBT IONQ
-
After-hours movers: CSX Corp, Interactive Brokers, Novo Nordisk, Lilly
-
Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
-
Citizens Reiterates Market Outperform Rating on ProQR Therapeutics N.V. (PRQR)
-
Erste Group Upgrades Eli Lilly (LLY) to Buy, 'expect Eli Lilly to gain market share relative to its peers'
-
Lilly to present Verzenio survival data at ESMO meeting
-
Abbvie (ABBV) PT Raised to $284 at Piper Sandler
-
TD Cowen says this is 'a must-own stock'
-
Eli Lilly (LLY) PT Raised to $948 at Guggenheim
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Former FDA vaccine regulator Peter Marks joins Eli Lilly
-
Lilly reports four-year remission data for ulcerative colitis drug
-
TD Cowen Calls Eli Lilly (LLY) 'A Must-Own Stock'
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put with a focus on a spreader of November 850 calls
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
-
Guggenheim Reiterates Buy Rating on Eli Lilly (LLY)
-
CFRA Upgrades Eli Lilly (LLY) to Buy (earlier)
-
Lilly opens new Gateway Labs facility in San Diego
-
Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY)
-
Lilly to build $6.5 billion manufacturing facility in Houston
-
UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
-
Eli Lilly partners with Prellis Biologics on antibody drug discovery
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
Trump: tariffs will get countries to agree to drug pricing plan
-
BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY), full ATTAIN-1 data 'broadly positive'
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY)
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY)
-
Berenberg Downgrades Eli Lilly (LLY) to Hold
-
FDA issues warning letter to Eli Lilly over ZEPBOUND promotional video
-
FDA warns Eli Lilly over misleading weight-loss drug promotion
-
Eli Lilly plans $5 billion Virginia manufacturing facility
-
How are GLP-1 drugs changing U.S. grocery behavior?
-
Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
-
Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Eli Lilly launches AI platform for biotech drug discovery
-
Lilly's Jaypirca shows improved survival in treatment-naive CLL study
-
FDA grants breakthrough therapy status to Lilly's lung cancer drug olomorasib
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
